Back to today’s briefing

Story perspectives

New Obesity Pill Orforglipron Shows Promising 11.2% Weight Loss

9/17/2025

23 2 Full Breakdown

Summary

Story summary

Orforglipron, a new obesity pill, achieved an average weight loss of 11.2% over 17 months in a trial with 3,127 patients.
This GLP-1 agonist also enhances blood pressure, waist size, and cholesterol levels.
Side effects are primarily mild to moderate gastrointestinal issues.
Taken once daily, it offers a more accessible alternative to injections.
Eli Lilly plans to submit it for regulatory review, with a potential global launch next year.

1 of 1

Story summary

Orforglipron, a new obesity pill, achieved an average weight loss of 11.2% over 17 months in a trial with 3,127 patients.
This GLP-1 agonist also enhances blood pressure, waist size, and cholesterol levels.
Side effects are primarily mild to moderate gastrointestinal issues.
Taken once daily, it offers a more accessible alternative to injections.
Eli Lilly plans to submit it for regulatory review, with a potential global launch next year.